Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions

Blood

Volumn 97, Issue 4, 2001, Pages 994-1000

  Peggs, K ^a   Verfuerth, S ^a   Mackinnon, S ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; THYMIDINE; TRITIUM; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL TRANSPLANTATION; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DENDRITIC CELL; FIBROBLAST; HUMAN; HUMAN CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRION; VIRUS INFECTIVITY;

EID: 0035865520     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.994     Document Type: Article

References (49)

1. Nonbacterial pneumonia after allogeneic marrow transplantation: A review often years' experience
2. Risk factors for cytomegalovirus infection after human marrow transplantation
3. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
4. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
5. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
6. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
7. Dendritic cells: Unique leukocyte populations which control the primary immune response
8. Dendritic cells and the control of immunity
9. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
10. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
11. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae
12. Dendritic cells efficiently induce protective antiviral immunity
13. Molecular analysis of T cell repertoires: Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence
14. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
15. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
16. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
17. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegaiovirus infections
18. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients
19. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
20. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
21. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
22. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
23. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
24. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
25. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
26. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients
27. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique
28. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma
29. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction
30. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
31. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
32. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
33. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro
34. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones
35. Principles for adoptive T cell therapy of human viral diseases
36. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
37. Binding of immunogenic peptides to Ia histocompatibility molecules
38. Cytotoxic T cells recognize fragments of the influenza nucleoprotein
39. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones
40. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
41. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
42. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
43. Human cytomegalovirus-specific cytotoxic T cells: Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses
44. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
45. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
46. +-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
47. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation
48. Predicting graft-versus-host disease in HLA-identical bone marrow transplant: A comparison of T-cell frequency analysis and a human skin explant model
49. Human cytomegalovirus-specific cytotoxic T lymphocytes: Requirements for in vitro generation and specificity